Company intelligence / Profile preview
Athenex
Buffalo, New York, United Statesathenex.com ↗
- Ownership
- Public · ATNX
- Employees
- ~599
- Development stage
- Other
01
Overview
Athenex has multiple products in development and on the market, including sterile high-potency oncology drugs. The company completed construction of a manufacturing facility in Dunkirk, New York in 2020, with operations expected to begin in Q2 2021.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculessterile high-potency oncology drugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
State University of New York Polytechnic Institute (SUNY Polytechnic Institute)Hanmi Pharmaceuticals
Beyond the preview
Go deeper on Athenex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Athenex.